Back to search results

Navigator-Assisted Hypofractionation (NAVAH) for Breast and Prostate Cancer Radiation Therapy

This study, called NAVAH, is looking at how well people with breast or prostate cancer complete their radiation therapy. It specifically focuses on African American, Native American, and Hispanic patients. The study wants to see if patient navigators (people who help guide you through your medical care) can help patients finish their treatment and stick to their care plan. You would complete surveys before and after your treatment, and if you choose to do the surveys, you would be offered navigation assistance. The main goal is to see how many patients complete their radiation therapy, measured at 6 months. The study plans to enroll 420 participants, but its current recruitment status is unclear.

Study design
This is an observational study, meaning researchers will watch and collect information without giving specific treatments. It plans to include 420 participants.
What's involved
You would complete a pre-treatment questionnaire at the time of consent and a post-treatment questionnaire. These can be done in person, over the phone, or through a mobile app.
Compensation
Not stated in the trial record.
Follow-up
The study measures completion of radiation therapy at 6 months.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07014618

Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer

Recruiting
Not specifiedAges 18+Observational
University of Oklahoma
~420 participants
Updated 2025-12-17 on ClinicalTrials.gov
What's tested:Pre & Post SurveysOpt Out of Questionnaire

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Number of Patients Who Complete Radiation Therapy
Measured over 6 months

Conditions

Breast Cancer
Prostate Cancer

Explore related trials

Breast CarcinomaProstate Carcinoma

Where it's being run

1 sites across 1 states
Oklahoma1

Study leadership

  • Shearwood McClelland III, MD · PRINCIPAL_INVESTIGATOR · OU Health Stephenson Cancer Center

Who to contact

Lead Onco Nurse
[email protected]
405-271-8777
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer.
Subjects must be 18 years of age or older. This study requires informed consent by the subject.
Subjects must be of African American race, Native American race, or Hispanic ethnicity.
Subjects scheduled to undergo RT for Cancer Treatment.
Subjects must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion

Subjects NOT of African American race, Native American race or Hispanic ethnicity.
Subjects WITHOUT histologically/cytologically confirmed Breast or Prostate Cancer.
Subjects younger than 18 years old.

What this trial measures

  • Number of Patients Who Complete Radiation Therapy6 months

    Survey-based methods will be used to assess barriers facing under-represented minority cancer patient access to patient navigation. This study will use a patient-completed, culturally sensitive survey adapted from "Walking Forward," a patient navigator program providing culturally appropriate community education on cancer, screening and treatment, to include barriers to specific RT regimens, and concerns regarding transportation.